Zepbound Copay Assistance Even with insurance, some individuals face high copays for Zepbound medication
Beyond 2024, we think Roche is capable of mid- or even high-single-digit annual growth (and core operating margins remaining in the mid-30s), with higher growth possible if these in-licensed programsor in-house programs like Alzheimers disease drug candidate trontinemab or oncology drug candidate tiragolumabreach the market
Fast shipping, all the supplies needed, and effective product
pharmaphorum pharmaphorum Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency Published Feb 2, 2026 In this weeks Top Stories, AstraZeneca deepened its ties with China, pledging $15 billion in investment and signing a big $18.5 billion alliance with CSPC Pharma for obesity and diabetes drugs
Even when theyre not truly oral products, theyre often lumped into the same conversation as oral skin tanners , so its important to understand that this whole category is largely unregulated and potentially risky